SHEPHERD THERAPEUTICS FOUNDER AND CEO DAVID HYSONG NAMED TO FORBES 30 UNDER 30: HEALTHCARE

For Immediate Release

Contact:
Lacie Randall
Chief Creative Officer
lacie@shepherd.bio

SHEPHERD THERAPEUTICS FOUNDER AND CEO DAVID HYSONG NAMED TO FORBES 30 UNDER 30: HEALTHCARE

Rare Cancer Patient Recognized for Contribution to Healthcare Sector

CAMBRIDGE, MA— January 3, 2017 — Today, SHEPHERD Founder and CEO David Hysong was announced as a member of the Forbes 30 Under 3o Class of 2017. As described on Forbes.com, the annual list seeks to honor “the brightest young entrepreneurs, breakout talents and change agents in 20 different sectors.” Mr. Hysong was selected for the Healthcare sector, joining an impressive class boasting a United Nations commissioner, postdoctoral fellows at the nation’s best medical schools, and several healthcare company founders.
Before being diagnosed with Adenoid Cystic Carcinoma—a rare and untreatable head-and-neck cancer—Mr. Hysong investigated the sexual enslavement of children in Cambodia, studied at Harvard Divinity School, and trained to join U.S. Military Special Operations. After learning about his own disease and meeting many rare cancer patients faced with a similar lack of therapies, Mr. Hysong founded SHEPHERD, a biotech company focused on finding treatments for rare cancers. In 2016, Mr. Hysong assembled a team of experts in the field and raised $6.5 million in angel investments.
“Thank you to Forbes and everyone who made this possible, especially the SHEPHERD team,” said Mr. Hysong. “I am humbled and incredibly energized to be chosen for the Forbes 30 Under 30 Class of 2017. SHEPHERD made great strides in 2016 and making the Forbes list is an encouraging affirmation of that. In 2017 I look forward to continue fighting for our mission of saving the life of every individual with rare cancer.”
About Forbes 30 Under 30
The list is an annual publication by Forbes magazine recognizing individuals under 30 years old for their contributions to one of 20 sectors. Forbes reporters carefully research nominees before the judges—field experts and 30 Under 30 alums—finally select a class of 30 individuals for each sector. This meticulous process yields a highly selective group: the acceptance rate for the 30 Under 30 Class of 2017 was <4%.
About SHEPHERD Therapeutics
The mission of SHEPHERD is to cure rare cancers. Founded by a rare cancer patient, SHEPHERD is a biotechnology company relentlessly focused on using deep disease understanding, development expertise, and an unwavering commitment to save people dying of neglected rare cancers. SHEPHERD is changing the traditional economics and timeline of drug development, delivering better treatments faster for patients who previously had none. To join the mission or learn more, visit shepherd.bio.

###

SHEPHERD THERAPEUTICS APPOINTS CMO, COO, AND STRATEGIC RESEARCH ANALYST

For Immediate Release

Contact:
Lacie Randall
Chief Creative Officer
lacie@shepherd.bio

SHEPHERD THERAPEUTICS APPOINTS CMO, COO, AND STRATEGIC RESEARCH ANALYST
Mission-Driven Biotech Strengthens Resources to Cure Rare Cancers

CAMBRIDGE, MA— December 14, 2016 — SHEPHERD Therapeutics, a life sciences company founded to cure rare cancers, today announced the appointments of Abby Reiner, Elizabeth Hostetter, and Jon Goetz to serve as Chief Marketing and Business Development Officer, Chief Operating Officer, and Strategic Research Analyst, respectively. “I am very excited to welcome Abby, Elizabeth, and Jon to the Shepherd team,” said David Hysong, patient, founder, and CEO of Shepherd. “These three individuals exemplify our desire to create a diverse team that brings a wide array of skills and experiences to our work. I am confident that Abby, Elizabeth, and Jon will each bring a unique perspective to our team dynamic and contribute profoundly to cure rare cancers.”

“I was really motivated by David’s story. His and the countless others’ I’ve heard since joining SHEPHERD are so powerful that if my talents can contribute to SHEPHERD’s mission to cure rare cancers, I’m in,” said Ms. Reiner. “SHEPHERD also has a world class team of experts of which I’m thrilled and humbled to be a part.”

“I am thrilled to be joining SHEPHERD at this pivotal moment,” said Ms. Hostetter. “David has been incredibly thoughtful in putting this team together. We share an energized commitment to change the outlook for patients with rare cancer and, in a few short months, have made extraordinary progress towards that goal. We are moving into the new year with an array of dynamic projects and I look forward to driving the momentum forward into the next phase of growth for SHEPHERD.”

“Although my experience lies in education, the mission of SHEPHERD embodies my passion in cultivating the wellbeing and personal flourishing of all people, regardless of situation,” said Mr. Goetz. “Health, like education, is a fundamental human right and I am excited to support Shepherd’s work through research and collaboration with the rest of the team.”

About Abby Reiner
Abby Reiner comes to SHEPHERD with a wealth of branding experience gained through work with the Wounded Warrior Project, PGA Tour, and Nike Golf Learning Centers. In her 10 years with the Wounded Warrior Project, Ms. Reiner established the brand architecture, visual brand assets, physical presence, and tangible brand experiences. Ms. Reiner led her team at Wounded Warrior in a 10-year anniversary campaign that encompassed a documentary film series picked up by MSNBC and Netflix. Ms. Reiner has been published by the Journal of Brand Strategy for her work in nonprofit brand protection and holds a B.S. in Marketing from Arizona State University.

About Elizabeth Hostetter
Prior to SHEPHERD, Elizabeth Hostetter worked as a consultant at Bain & Company where she advised companies across sectors to grow profitably, optimize costs and launch commercial products. Ms. Hostetter has experience in healthcare investment banking for Goldman Sachs and scientific research at the Broad Institute of MIT and Harvard. While completing her Master’s Studies in Business, Ms. Hostetter worked at Third Rock Ventures, a life sciences venture capital firm. Ms. Hostetter holds a B.A. in Human Biology from Stanford University and an M.B.A. from Harvard Business School.

About Jon Goetz
Jon Goetz joins SHEPHERD with a passion for research and instruction. As an undergraduate, Mr. Goetz worked with Breakthrough Collaborative, a national nonprofit focused on increasing academic opportunity for highly motivated, underserved students. Mr. Goetz holds an A.B. in History and a secondary in English Literature from Harvard University.

About SHEPHERD Therapeutics
The mission of SHEPHERD Therapeutics is to cure rare cancers. Founded by a rare cancer patient, SHEPHERD is a life sciences company relentlessly focused on using deep disease understanding, development expertise, and unwavering commitment to save people dying of neglected rare cancers. Shepherd is changing the traditional economics and timeline of drug development, delivering better treatments faster for patients who previously had none. To join the mission or learn more, visit shepherd.bio.

###

SHEPHERD THERAPEUTICS APPOINTS CHIEF RESEARCH OFFICER AND CHIEF CREATIVE OFFICER

For Immediate Release

Contact:
Lacie Randall
Chief Creative Officer
lacie@shepherd.bio

SHEPHERD THERAPEUTICS APPOINTS CHIEF RESEARCH OFFICER AND CHIEF CREATIVE OFFICER
Life Sciences Company Expands Team

CAMBRIDGE, MA— December 14, 2016 — SHEPHERD Therapeutics, a life sciences company founded to cure rare cancers, today announced the appointments of Jamie Dempsey Barber, PhD and Lacie Randall to serve as Chief Research Officer and Chief Creative Officer, respectively. “The appointments of Jamie and Lacie add crucial value to SHEPHERD’s scientific projects and marketing strategy,” said SHEPHERD founder and CEO David Hysong. “Jamie and Lacie bring incredible dedication to the company along with considerable experience in their respective fields. I look forward to working with both of them to create a patient-oriented company that delivers dynamic therapies for rare cancers.”

“After meeting David and hearing his story, I became infected with his excitement and determination to fight for patients of rare cancers. Once I started digging into the state of research and really understanding how sparse the drug development for rare cancers is I realized how great an impact SHEPHERD could have for these neglected patients,” said Dr. Dempsey Barber. “My role at SHEPHERD includes all things cancer biology related, including working with our team to identify rare cancers and determine the best therapeutic path forward.”

“This position at SHEPHERD allows me to utilize my experience in both nonprofit and for-profit companies to tell a story that desperately needs telling: the story of millions of patients suffering from rare cancers,” said Ms. Randall. “I am passionate about using innovative design to communicate this story in a thoughtful, urgent way that stresses both the scope of the problem and the dignity of the individuals fighting rare cancer day to day.”

About Dr. Jamie Dempsey Barber
Before joining SHEPHERD, Dr. Dempsey Barber was the head teaching fellow for both molecular and cellular biology courses at Harvard. Additionally, she instructed “The Biology of Cancer,” a course taught through the Harvard Extension School. During her Ph.D. studies, Dr. Dempsey Barber worked in Dr. John Blenis’s lab, focusing on the mTOR signaling pathway and alternative splicing regulation. Previously, she spent two years as a post-baccalaureate fellow at the National Cancer Institute, where she studied in Dr. Jonathan Wiest’s laboratory, focusing on the MAP kinase MAP3K8. Dr. Dempsey Barber holds a B.S. from Austin Peay State University and a Ph.D. in cell biology from Harvard University.

About Lacie Randall
Prior to SHEPHERD, Ms. Randall has helped create multiple American Advertising Award-winning campaigns for both nonprofit and for-profit organizations. Working with Major League Baseball, the National Football League, Publix, and Hermès, Ms. Randall has developed an appreciation for innovative design and creative resourcing. Ms. Randall holds a B.A. in International Affairs and Communication from The Florida State University.

About SHEPHERD Therapeutics
The mission of SHEPHERD Therapeutics is to cure rare cancers. Founded by a rare cancer patient, SHEPHERD is a life sciences company relentlessly focused on using deep disease understanding, development expertise, and unwavering commitment to save people dying of neglected rare cancers. SHEPHERD is changing the traditional economics and timeline of drug development, delivering better treatments faster for patients who previously had none. To join the mission or learn more, visit shepherd.bio.

###

SHEPHERD THERAPEUTICS ANNOUNCES DR. JOHANNE KAPLAN AS CHIEF SCIENTIFIC OFFICER

For Immediate Release

Contact:
Abby Reiner
Chief Marketing Officer
abby@shepherd.bio

SHEPHERD THERAPEUTICS ANNOUNCES DR. JOHANNE KAPLAN AS CHIEF SCIENTIFIC OFFICER

Biotech Veteran Joins the Mission to Cure Rare Cancer

CAMBRIDGE, MA— December 14, 2016 — SHEPHERD Therapeutics, a life sciences company founded to cure rare cancers, today announced it has appointed Johanne Kaplan, PhD, to the position of Chief Scientific Officer. In this role, Dr. Kaplan will oversee and support SHEPHERD’s scientific programs. “The appointment of Dr. Kaplan is an exciting addition to the SHEPHERD team,” said CEO and founder David Hysong. “Dr. Kaplan brings an impressive skill set and wealth of experience to SHEPHERD and will substantively contribute to the planning and development of our project portfolio.”

“I am very excited to be joining the dynamic team at SHEPHERD and I look forward to helping execute on the inspiring mission of developing cures for rare cancers,” said Dr. Kaplan.

About Dr. Johanne Kaplan
Prior to Shepherd, Dr. Kaplan spent 24 years at Genzyme, most recently serving as Vice President of Research. In this position, Dr. Kaplan directed pioneering research leading to the implementation of multiple clinical trials in the fields of gene therapy, autoimmunity, and oncology. Dr. Kaplan also led Genzyme’s successful development of Lemtrada (alemtuzumab) and Aubagio (teriflunomide) for the treatment of relapsing-remitting multiple sclerosis. Her work has resulted in over 60 scientific publications and multiple patents. Dr. Kaplan holds a B.Sc. and a Ph.D. in Microbiology and Immunology from McGill University in Montreal, Canada and conducted post-doctoral studies at the Albert Einstein College of Medicine in New York.

About SHEPHERD Therapeutics
The mission of SHEPHERD Therapeutics is to cure rare cancers. Founded by a rare cancer patient, SHEPHERD is a life sciences company relentlessly focused on using deep disease understanding, development expertise, and unwavering commitment to save people dying of neglected rare cancers. SHEPHERD is changing the traditional economics and timeline of drug development, delivering better treatments faster for patients who previously had none. To join the mission or learn more, visit shepherd.bio.

###

SHEPHERD THERAPEUTICS HOSTS NASHVILLE HOLIDAY CONCERT

For Immediate Release

Contact:
Lacie Randall
Chief Creative Officer
lacie@shepherd.bio

SHEPHERD THERAPEUTICS HOSTS NASHVILLE HOLIDAY CONCERT
Local Biopharma Company Supports Local Music Scene

Nashville, TN— November 29, 2016 — Leave it to an eclectic town like Nashville to bring together Grammy-award-winning musicians, a famous boy band member, an entertainment networking group featured in Forbes, and a 29-year-old Harvard entrepreneur who founded his own biotech company to celebrate the holidays. That’s exactly what’s happening tonight at 8:00pm at The Basement East, as the annual Young Entertainment Professionals (YEP) “Pause for the Claus” event takes place to give young musicians and music industry professionals alike an opportunity to mix, mingle, and jingle.
SHEPHERD Therapeutics patient-founder David Hysong had this to say about sponsoring such an event, “We chose to plant roots in Nashville because we knew it was a community of friends and a place to find people willing to help one another. Nashville has already proven a wonderful home both for me and for SHEPHERD, so we were grateful for the opportunity to help and support Nashville’s talented young artists through our involvement with YEP.”

Known as Music City, Nashville has always been known as the home of country music, but has in recent years, beckoned many other genres of artists and musicians, including one of the members of N*SYNC, Chris Kirkpatrick. Kirkpatrick is just one of the many artists performing tonight in an effort to bring together the community of talent in one beloved platform.

“We’re very excited to have SHEPHERD on board as a sponsor for one of our largest networking events of the year. It has always been important to our members we partner with organizations that not only assist financially, but also serve as mentors and take an interest in what we are doing to help progress the state of the music industry. David and the team at SHEPHERD have been an excellent example of that,” explained incoming YEP Executive Director, Amelia Varni.

About SHEPHERD Therapeutics
The mission of SHEPHERD Therapeutics is to cure rare cancers. Founded by a rare cancer patient, SHEPHERD is a life sciences company relentlessly focused on using deep disease understanding, development expertise, and unwavering commitment to save people dying of neglected rare cancers. SHEPHERD is changing the traditional economics and timeline of drug development, delivering better treatments faster for patients who previously had none. To join the mission or learn more, visit shepherd.bio.

###

SHEPHERD THERAPEUTICS TO FOCUS ON RARE CANCER CURES

For Immediate Release

Contact:
Lacie Randall
Chief Creative Officer
lacie@shepherd.bio

SHEPHERD THERAPEUTICS TO FOCUS ON RARE CANCER CURES
Rare Cancer Patient Founds Biopharma Company To Treat Fellow Rare Cancer Patients

CAMBRIDGE, MA— November 24, 2016 — David Hysong is fighting for his life and using his story to save the lives of others. After being diagnosed with Adenoid Cystic Carcinoma (ACC), a rare cancer for which there is no cure or approved therapy, David reached out to former Genzyme senior vice president Gene Williams. Together they founded the rare cancer-focused biopharma company, SHEPHERD Therapeutics, on January 1, 2016. SHEPHERD will research and develop novel therapies to treat cancers similar to ACC and will be a voice for patients previously neglected by the pharmaceutical industry.

Rare Isn’t Rare
“5.9 million people are diagnosed with a rare cancer every year. That’s forty-two percent of all cancer patients. So what the public needs to understand is that ‘rare’ really isn’t rare,” explained David. “On top of that, patients with a rare cancer are two and a half times less likely to have a therapy developed for their disease than those diagnosed with non-rare cancers. For the 250 forms of cancer listed by the American Cancer Society, only 49 have approved treatments. I wasn’t about to stand there along with 6 million others and wait to die. It was time to do something about it.”

SHEPHERD is breaking new ground, not only in its intentional and singular focus on rare cancer but also in its innovative business model which combines a diversified and platform-agnostic portfolio, strong relationships with disease-specific research foundations, and the ability to leverage top industry talent and expertise using a virtual model. As described by Gene Williams, “SHEPHERD is an early exemplar of one of the most important trends in medicine and health – patient empowerment and engagement…SHEPHERD is a pharmaceutical company by patients, for patients. It is truly a people’s biotech.”

How SHEPHERD Works
SHEPHERD guides disease-specific therapies and innovations from research through development to save lives. Over the past six months, Mr. Hysong has assembled an impressive staff of former pharmaceutical executives who believe in the vision and share his commitment to the SHEPHERD mission. SHEPHERD now employs a full staff of scientists dedicated to rare cancer therapies, as well as a team of research, marketing and business development fellows. Together, they combine wide-ranging expertise in disease biology, cutting-edge technological advances, government regulatory processes and the pharmaceutical industry. SHEPHERD is dedicated to developing therapeutics for all patients of rare, underfunded, and otherwise neglected cancers.

About SHEPHERD Therapeutics
The mission of SHEPHERD Therapeutics is to cure rare cancers. Founded by a rare cancer patient, SHEPHERD is a life sciences company relentlessly focused on using deep disease understanding, development expertise, and unwavering commitment to save people dying of neglected rare cancers. SHEPHERD is changing the traditional economics and timeline of drug development, delivering better treatments faster for patients who previously had none. To join the mission or learn more, visit shepherd.bio.

###